These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 6326283

  • 1. [Treatment of advanced ovarian cancer].
    de Gramont A, Krulik M, Pigne A, Brissaud P, Sirinelli A, Hubert D, Zylberait D, Debray J.
    Sem Hop; 1984 Mar 29; 60(14):957-60. PubMed ID: 6326283
    [Abstract] [Full Text] [Related]

  • 2. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A, Drolet Y, Louvet C, Dray C, Krulik M, Pigné A, Lavoie A, Painchaud M, Blouin R, Tessier C.
    J Gynecol Obstet Biol Reprod (Paris); 1986 Mar 29; 15(1):105-9. PubMed ID: 3084619
    [Abstract] [Full Text] [Related]

  • 3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ, Lele SB.
    Cancer Treat Rep; 1984 Dec 15; 68(12):1433-8. PubMed ID: 6439408
    [Abstract] [Full Text] [Related]

  • 5. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW, Coleman M, Silver RT, Ballard WP.
    Cancer Treat Rep; 1985 Jun 15; 69(6):689-93. PubMed ID: 3926310
    [Abstract] [Full Text] [Related]

  • 6. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G.
    Gynecol Oncol; 2001 May 15; 81(2):150-9. PubMed ID: 11330942
    [Abstract] [Full Text] [Related]

  • 7. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
    Salzer H, Gitsch E, Dittrich C, Sevelda P, Karrer K, Schemper M, Stempel-Smekal G, Langer M, Wagner G, Rainer H.
    Geburtshilfe Frauenheilkd; 1985 Nov 15; 45(11):761-8. PubMed ID: 3908214
    [Abstract] [Full Text] [Related]

  • 8. [Cisplatin, adriamycin and cyclophosphamide combination chemotherapy of epithelial ovarian cancer].
    Sawada M, Ozaki M, Inagaki M, Hongo J, Hirota Y, Takayama K, Arimoto Y, Wada T, Taki I, Yanagita T.
    Gan To Kagaku Ryoho; 1987 Dec 15; 14(12):3301-4. PubMed ID: 3120644
    [Abstract] [Full Text] [Related]

  • 9. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
    Blumenschein GR, DiStefano A, Caderao J, Fristenberg B, Adams J, Schweichler LH, Drinkard L.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 2):2633-7. PubMed ID: 10068266
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ, Braly P, Cecchi G, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Parker P, Stein A, Cho J, Smith E, Coluzzi P, Najera L, Johnson D, Womack E, Doroshow JH.
    Gynecol Oncol; 1999 Dec 15; 75(3):419-26. PubMed ID: 10600300
    [Abstract] [Full Text] [Related]

  • 11. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2006 Aug 15; 102(2):285-91. PubMed ID: 16516283
    [Abstract] [Full Text] [Related]

  • 12. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
    Krommer K, Keller G, Csaba I, Garadnay B, Göcze P.
    Zentralbl Gynakol; 1990 Aug 15; 112(17):1105-10. PubMed ID: 2264421
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA, Julian CG, Richardson RL, Burnett L, Hande KR, Oldham RK.
    Obstet Gynecol; 1981 Aug 15; 58(2):199-205. PubMed ID: 6789265
    [Abstract] [Full Text] [Related]

  • 19. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM, Copeland LJ, Kavanagh JJ, Stringer CA, Saul PB, Wharton JT.
    Obstet Gynecol; 1987 Nov 15; 70(5):765-9. PubMed ID: 3658288
    [Abstract] [Full Text] [Related]

  • 20. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
    Pater JL, Carmichael JA, Krepart GV, Fraser RC, Roy M, Kirk ME, Levitt M, Brown LB, Wilson KS, Shelley WE.
    Cancer Treat Rep; 1987 Mar 15; 71(3):277-81. PubMed ID: 3102056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.